MRG006A for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have an advanced solid tumor (cancer that has spread or cannot be removed by surgery).
- You need to provide a tumor tissue sample for testing of GPC3 and P53 markers.
- You must be able to take care of yourself (ECOG 0 or 1).
- You cannot have serious heart, lung, or bleeding problems, or active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing an experimental drug called MR001 (a bispecific antibody) for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and how well it works.
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
This trial tests a new drug called MRG007 combined with other treatments for people with advanced colorectal cancer that cannot be removed by surgery or has spread. It aims to see if the combination is safe and effective.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.